A healthcare company on a mission to produce a multi-cancer early detection (MCED) test so patients have more chance of being cured, has produced 'exciting results' from a study.
SYMPLIFY Results Demonstrate Strong Performance of GRAIL's Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs and Symptoms Results in Press